Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 22;12(8):e12190.
doi: 10.1002/clt2.12190. eCollection 2022 Aug.

Characterization, epidemiology and risk factors of multiple drug allergy syndrome and multiple drug intolerance syndrome: A systematic review

Parbir K Jagpal  1 , Saad Alshareef  2 , John F Marriott  1 , Mamidipudi Thirumala Krishna  2   3
Affiliations

Characterization, epidemiology and risk factors of multiple drug allergy syndrome and multiple drug intolerance syndrome: A systematic review

Parbir K Jagpal et al. Clin Transl Allergy. .

Abstract

Background: Multiple drug allergy and multiple drug intolerance syndrome (MDAS/MDIS) labels are an impediment to clinical care and knowledge regarding these conditions is limited. This systematic review investigated the characterization, epidemiology, risk factors, clinical impact and pharmaco-economics of MDAS and MDIS.

Methods: Systematic literature search across 11 databases (01 January 2000-06 November 2020) for MDIS, MDAS and related terminology. Studies were reviewed for quality of evidence and risk of bias by employing Critical Appraisal Skills Programme cohort study checklist. A narrative synthesis approach facilitated by systematic textual descriptions, tabulation and thematic analysis was adopted.

Results: There was heterogeneity in terminology and methodology. Few studies applied standard drug allergy diagnostic methods. There is some evidence to suggest that multiple drug hypersensitivity syndrome (MDHS; i.e., confirmed allergies in MDAS) is a distinct clinical entity. Prevalence of MDIS and MDAS labels in unselected & selected populations varied between 2.1%-6.4% & 4.9%-90% and 1.2% & 0%-36% respectively. Reported risk factors included female gender, increasing age, body mass index, anxiety, depression, co-morbidities, concurrent allergies and increased healthcare utilization. Drugs commonly implicated were antibiotics and non-steroidal anti-inflammatory drugs. No studies relating to clinical impact and pharmaco-economics were found.

Conclusion: There is considerable burden of MDAS and MDIS labels. Data needs cautious interpretation as majority of studies described involved unverified labels. Despite this limitation and heterogeneity of studies, there is some evidence to suggest that MDHS is a distinct clinical entity. Well-designed multi-centre studies applying standardized terminology and diagnostic methodology are needed to gain further insight into these conditions.

Keywords: multiple drug allergy; multiple drug allergy syndrome; multiple drug hypersensitivity; multiple drug intolerance; multiple drug intolerance syndrome.

PubMed Disclaimer

Conflict of interest statement

Mamidipudi Thirumala Krishna's department received educational grants from ALK Abello, Allergy Therapeutics, MEDA and other pharmaceutical companies for annual PracticAllergy course. Mamidipudi Thirumala Krishna has received grants from NIHR, MRC CiC, GCRF and FSA outside of the work presented in this manuscript. Other authors have none to declare.

Figures

FIGURE 1
FIGURE 1
PRISMA 2020 flow diagram for new systematic reviews: searches of databases, registers and other sources, exclusion and included studies. ** exclusion criteria: abstract only publications, conference presentations, letters, grey literature, reviews, and meta‐analyses
See this image and copyright information in PMC

References

    1. Guidance on adverse drug reactions: Medicines and Healthcare products Regulatory Agency: Medicines & Halthcare Products Regulatory Agency. https://assets.publishing.service.gov.uk/government/uploads/system/uploa...
    1. Drug Allergies: World Allergy Organization. https://www.worldallergy.org/education‐and‐programs/education/allergic‐d...
    1. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832‐836. 10.1016/j.jaci.2003.12.591 - DOI - PubMed
    1. Demoly P, Adkinson NF, Brockow K, et al. International consensus on drug allergy. Allergy. 2014;69(4):420‐437. 10.1111/all.12350 - DOI - PubMed
    1. Drug allergy: diagnosis and management Clinical guideline [CG183]: National Institute for Health and Care Excellence. Accessed November 11, 2021. https://www.nice.org.uk/guidance/cg183/chapter/Introduction - PubMed